These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Benefit-Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER. Raskob GE; Spyropoulos AC; Spiro TE; Lu W; Yuan Z; Levitan B; Suh E; Barnathan ES J Am Heart Assoc; 2021 Nov; 10(22):e021579. PubMed ID: 34755519 [TBL] [Abstract][Full Text] [Related]
7. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. Ramacciotti E; Barile Agati L; Calderaro D; Aguiar VCR; Spyropoulos AC; de Oliveira CCC; Lins Dos Santos J; Volpiani GG; Sobreira ML; Joviliano EE; Bohatch Júnior MS; da Fonseca BAL; Ribeiro MS; Dusilek C; Itinose K; Sanches SMV; de Almeida Araujo Ramos K; de Moraes NF; Tierno PFGMM; de Oliveira ALML; Tachibana A; Chate RC; Santos MVB; de Menezes Cavalcante BB; Moreira RCR; Chang C; Tafur A; Fareed J; Lopes RD; Lancet; 2022 Jan; 399(10319):50-59. PubMed ID: 34921756 [TBL] [Abstract][Full Text] [Related]
8. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. Cohen AT; Spiro TE; Büller HR; Haskell L; Hu D; Hull R; Mebazaa A; Merli G; Schellong S; Spyropoulos AC; Tapson V; N Engl J Med; 2013 Feb; 368(6):513-23. PubMed ID: 23388003 [TBL] [Abstract][Full Text] [Related]
9. Rivaroxaban for thromboprophylaxis among patients recently hospitalized for acute infectious diseases: a subgroup analysis of the MAGELLAN study. Cohoon KP; De Sanctis Y; Haskell L; McBane RD; Spiro TE J Thromb Haemost; 2018 Jul; 16(7):1278-1287. PubMed ID: 29753308 [TBL] [Abstract][Full Text] [Related]
10. Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. Carrier M; Abou-Nassar K; Mallick R; Tagalakis V; Shivakumar S; Schattner A; Kuruvilla P; Hill D; Spadafora S; Marquis K; Trinkaus M; Tomiak A; Lee AYY; Gross PL; Lazo-Langner A; El-Maraghi R; Goss G; Le Gal G; Stewart D; Ramsay T; Rodger M; Witham D; Wells PS; N Engl J Med; 2019 Feb; 380(8):711-719. PubMed ID: 30511879 [TBL] [Abstract][Full Text] [Related]
11. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. Goldhaber SZ; Leizorovicz A; Kakkar AK; Haas SK; Merli G; Knabb RM; Weitz JI; N Engl J Med; 2011 Dec; 365(23):2167-77. PubMed ID: 22077144 [TBL] [Abstract][Full Text] [Related]
12. Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty. Anderson DR; Dunbar M; Murnaghan J; Kahn SR; Gross P; Forsythe M; Pelet S; Fisher W; Belzile E; Dolan S; Crowther M; Bohm E; MacDonald SJ; Gofton W; Kim P; Zukor D; Pleasance S; Andreou P; Doucette S; Theriault C; Abianui A; Carrier M; Kovacs MJ; Rodger MA; Coyle D; Wells PS; Vendittoli PA N Engl J Med; 2018 Feb; 378(8):699-707. PubMed ID: 29466159 [TBL] [Abstract][Full Text] [Related]
13. Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. Rationale and Design of the CASSINI Trial. Khorana AA; Vadhan-Raj S; Kuderer NM; Wun T; Liebman H; Soff G; Belani C; O'Reilly EM; McBane R; Eikelboom J; Damaraju CV; Beyers K; Dietrich F; Kakkar AK; Riess H; Peixoto RD; Lyman GH Thromb Haemost; 2017 Nov; 117(11):2135-2145. PubMed ID: 28933799 [TBL] [Abstract][Full Text] [Related]
14. Rivaroxaban or Enoxaparin in Nonmajor Orthopedic Surgery. Samama CM; Laporte S; Rosencher N; Girard P; Llau J; Mouret P; Fisher W; Martínez-Martín J; Duverger D; Deygas B; Presles E; Cucherat M; Mismetti P; N Engl J Med; 2020 May; 382(20):1916-1925. PubMed ID: 32223113 [TBL] [Abstract][Full Text] [Related]